Update: FDA evaluating the risk of burns and scars with Zecuity (sumatriptan) migraine patch
Welcome to FDA Drug Safety Podcasts for health care professionals. This is Lesley Navin, Advanced Practice Nurse from the Division of Drug Information.
On June 10, 2016, Zecuity manufacturer, Teva Pharmaceuticals, announced it has decided to temporarily suspend sales, marketing, and distribution to investigate the cause of burns and scars associated with the Zecuity patch. Health care professionals should discontinue prescribing Zecuity. Patients should stop using any remaining patches and contact their prescribers for an alternative migraine medicine.
This is an update to the June 2, 2016 Drug Safety Communication that FDA is evaluating the risk of burns and scars with Zecuity (active ingredient sumatriptan) migraine patch.
A link to the Dear Healthcare Provider letter and the original communication can be found at www.fda.gov/DrugSafetyCommunications.
If you have drug questions, you can reach us at firstname.lastname@example.org.